Page Banner

Notifications & Alerts

Latest Notifications & Alerts

There will be no Panorama™ Non-Invasive Prenatal Test (NIPT) collections on December 25, 26, and January 1.
We have partnered with LifestyleRx to offer Canadians greater support in managing their health with prediabetes and Type 2 Diabetes
September 30th is National Day for Truth and Reconciliation. Our BC operations will be closed on Saturday, September 30, as well as Monday, October 2, 2023, to observe the holiday.
Due to a global supply shortage, the enzyme used for oxalate measurement is temporarily unavailable. LifeLabs has limited supply of the reagent and will suspend testing on September 28, 2023 in Ontario, and on October 5, 2023 in B.C.
The Infectious Diarrhea Panel (IDP) is a molecular panel test that replaces three separate tests for stool culture, O&P and C.difficile. It tests over 14 of the most common viruses, bacteria and protozoa that cause diarrhea.
Aug 24, 2023


**Update in Testing** This test is currently unavailable. We apologize for the inconvenience.
Effective July 10, 2023, Anti-cyclic citrullinated peptide (Anti-CCP) in-house testing will resume at LifeLabs and will be performed on the Roche Cobas e801 platform.
On May 29, 2023, we will be replacing the current high sensitivity Troponin T assay with the Abbott Alinity i high sensitivity cardiac Troponin I assay.
Starting March 30, 2023, LifeLabs will temporarily refer out all MSP testing for anti-CCP to the clinical laboratory at Vancouver General Hospital (VGH).
On Monday, February 27, we will be transitioning three assays from the instruments used at our Victoria Reference Laboratory onto the instruments used at our Burnaby Reference Laboratory.
This implementation will offer you and your patients an improved experience in managing health information by receiving test results electronically rather than through manual faxes.
LifeLabs has partnered with Natera, Inc. to offer SignateraTM, a molecular residual disease test that detects and monitors cancer status by examining an individual’s unique tumour genetic profile.